Renal denervation for hypertension: observations and predictions of a founder

Area of Science:

• Cardiovascular Medicine
• Interventional Cardiology
• Nephrology

Background:

• Resistant hypertension poses a significant clinical challenge.
• Catheter-based renal denervation (RDN) has emerged as a novel therapeutic approach.
• The 6-year anniversary of the first RDN procedure and 3-year follow-up data from the Symplicity HTN-1 trial warrant reflection.

Purpose of the Study:

• To review current observations on the efficacy, safety, and durability of RDN for resistant hypertension.
• To identify and discuss unresolved questions regarding RDN's long-term outcomes, patient selection, and procedural optimization.
• To predict the future clinical role of RDN in hypertension management.

Main Methods:

• Review of published 3-year follow-up data from the Symplicity HTN-1 trial.
• Analysis of clinical observations regarding blood pressure reduction and safety profiles.
• Discussion of current procedural techniques and future research directions.

Main Results:

• RDN appears efficacious, safe, and durable in the short-to-medium term for resistant hypertension.
• Unresolved questions remain regarding the permanence of blood pressure reduction, patient response variability, and impact on cardiovascular endpoints.
• Ongoing research is needed to optimize patient selection and procedural techniques.

Conclusions:

• Catheter-based RDN is a revolutionary therapy with established efficacy and safety for severe resistant hypertension.
• Further investigation is crucial to address long-term durability, optimal patient stratification, and potential application in milder hypertension.
• RDN is expected to gain a significant clinical role in managing severe hypertension within the next decade.